Does RUXOLITINIB Cause Therapy partial responder? 174 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 174 reports of Therapy partial responder have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.3% of all adverse event reports for RUXOLITINIB.
174
Reports of Therapy partial responder with RUXOLITINIB
0.3%
of all RUXOLITINIB reports
12
Deaths
8
Hospitalizations
How Dangerous Is Therapy partial responder From RUXOLITINIB?
Of the 174 reports, 12 (6.9%) resulted in death, 8 (4.6%) required hospitalization, and 3 (1.7%) were considered life-threatening.
Is Therapy partial responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 174 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Therapy partial responder?
CYCLOPHOSPHAMIDE (1,397)
RITUXIMAB (1,219)
DEXAMETHASONE (1,199)
PREDNISONE (1,176)
PEMBROLIZUMAB (1,125)
CARBOPLATIN (1,096)
DOXORUBICIN (834)
METHOTREXATE (775)
VINCRISTINE (707)
ETOPOSIDE (670)
Which RUXOLITINIB Alternatives Have Lower Therapy partial responder Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE